GENÉTICA MOLECULAR EN ONCOHEMATOLOGÍA
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoGlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2022
-
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 9, pp. 2367-2374.e3